Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBT Margin (2016 - 2025)

Historic EBT Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 237.65%.

  • CytomX Therapeutics' EBT Margin fell 2549900.0% to 237.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.87%, marking a year-over-year increase of 129800.0%. This contributed to the annual value of 23.24% for FY2024, which is 199600.0% up from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' EBT Margin is 237.65%, which was down 2549900.0% from 0.49% recorded in Q2 2025.
  • CytomX Therapeutics' 5-year EBT Margin high stood at 49.72% for Q4 2024, and its period low was 353.77% during Q1 2022.
  • Moreover, its 5-year median value for EBT Margin was 25.81% (2024), whereas its average is 117.51%.
  • As far as peak fluctuations go, CytomX Therapeutics' EBT Margin plummeted by -2680400bps in 2021, and later skyrocketed by 3396800bps in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' EBT Margin stood at 312.82% in 2021, then skyrocketed by 86bps to 43.61% in 2022, then surged by 116bps to 7.16% in 2023, then skyrocketed by 594bps to 49.72% in 2024, then plummeted by -578bps to 237.65% in 2025.
  • Its last three reported values are 237.65% in Q3 2025, 0.49% for Q2 2025, and 46.32% during Q1 2025.